cyclic-gmp and Idiopathic-Pulmonary-Fibrosis

cyclic-gmp has been researched along with Idiopathic-Pulmonary-Fibrosis* in 1 studies

Other Studies

1 other study(ies) available for cyclic-gmp and Idiopathic-Pulmonary-Fibrosis

Article	Year
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12 Our previous research demonstrated that phosphodiesterase-1 (PDE1) could work as a potential target against idiopathic pulmonary fibrosis. Nimodipine, a calcium antagonist commonly used to improve hypertension, was reported to have inhibition against PDE1. Herein, a series of nimodipine analogues were discovered as novel selective and potent PDE1 inhibitors after structural modifications. Compound Topics: Animals; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Idiopathic Pulmonary Fibrosis; Nimodipine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats	2022

Article

Year

Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.

Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

Our previous research demonstrated that phosphodiesterase-1 (PDE1) could work as a potential target against idiopathic pulmonary fibrosis. Nimodipine, a calcium antagonist commonly used to improve hypertension, was reported to have inhibition against PDE1. Herein, a series of nimodipine analogues were discovered as novel selective and potent PDE1 inhibitors after structural modifications. Compound

Topics: Animals; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 1; Idiopathic Pulmonary Fibrosis; Nimodipine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats

2022